Joel Pearlman
Retina Specialist · Sacramento, CANPI 1154430460
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,406 of the $32,572 with a category attached, or 62.6%. 26 manufacturers reported payments, led by Regeneron at 29.8% of the total. Reporting peaked in 2024 at $17,566 and has fallen 68.0% since, to $5,620 in 2025.
Across 122 payments — averaging $266.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$10K
- Amgen$9K
- Genentech USA, Inc.$3K
- Boehringer Ingelheim International GmbH$3K
- Ocular Therapeutix, Inc.$2K
- Alcon$2K
- plus $5K from 20 others
Across 1,288 payments — averaging $6432.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$4.1M
- Roche TCRC, Inc.$838K
- Boehringer Ingelheim$812K
- Regeneron$682K
- Eyepoint US, Inc.$555K
- Apellis Pharmaceuticals, Inc.$393K
- plus $912K from 9 others
What the payments were for
- Consulting fees$20,40663%
- Speaking & faculty fees$3,19610%
- Travel & lodging$2,2107%
- Food & beverage$5,92118%
- Other$8403%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 13 | $9,719 |
| Amgen | 15 | $8,991 |
| Genentech USA, Inc. | 19 | $2,849 |
| Boehringer Ingelheim International GmbH | 6 | $2,546 |
| Ocular Therapeutix, Inc. | 1 | $1,600 |
| Alcon | 6 | $1,536 |
| Carl Zeiss Meditec USA, Inc. | 1 | $840 |
| Carl Zeiss Meditec, Inc. | 2 | $720 |
| Regeneron Healthcare Solutions, Inc. | 10 | $689 |
| Alcon Research LLC | 1 | $490 |
| Apellis Pharmaceuticals, Inc. | 10 | $459 |
| Genentech, Inc. | 5 | $396 |
| Topcon Healthcare, Inc. | 6 | $348 |
| Biotissue Holdings Inc. | 4 | $346 |
| Astellas Pharma US Inc | 5 | $322 |
| Novartis | 5 | $272 |
| Harrow Eye, LLC | 1 | $119 |
| Alimera Sciences, Inc. | 3 | $66 |
| Boehringer Ingelheim | 1 | $65 |
| Biogen | 2 | $45 |
| Dutch Ophthalmic, USA | 1 | $45 |
| Astellas Pharma Global Development | 1 | $26 |
| Eyepoint US, Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
| Notal Vision, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$9,662
- PAVBLU$7,520
- Lucentis$1,780
- CIRRUS HD-OCT$1,490
- CLARUS$650
- VABYSMO$506
- Constellation$416
- EYLEA$376
- SUSVIMO$150
- BEOVU$110
- Hydrus Microstent$102
How this compares
$32,572 in reported general payments places this provider in the 80th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 26 | $12,881 |
| Prednisolone Acetate | 165 | $8,531 |
| RestasisCyclosporine | 11 | $6,352 |
| RhopressaNetarsudil Mesylate | 12 | $4,622 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $4,351 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,101 |
| Brimonidine Tartrate | 195 | $2,294 |
| Latanoprost | 213 | $2,009 |
| Brinzolamide | 15 | $1,971 |
| Timolol Maleate | 152 | $1,478 |
| ValacyclovirValacyclovir Hcl | 24 | $1,401 |
| Ofloxacin | 103 | $1,148 |
| Ketorolac Tromethamine | 55 | $1,076 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 45 | $626 |
| Dorzolamide Hcl | 44 | $625 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Sacramento
- Carlos Medina MendezSacramento$548K
- Margaret ChangSacramento$197K
- Glenn YiuSacramento$146K
- David TelanderSacramento$18K
- Maryam GhiassiSacramento$10K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.